Objectives: Long-term results at week 96 are needed to evaluate the capacity of the darunavir/ritonavir monotherapy strategy to maintain a sustained control of the HIV-1 viral load.
Introduction
Two randomized studies-the MONET and MONOI studies-have established the capacity of darunavir/ritonavir monotherapy (monotherapy arm) to maintain viral suppression compared with darunavir/ritonavir plus two nucleoside analogues (tripletherapy arm) in patients with suppressed viraemia. In the MONET study, 86.2% of monotherapy-arm patients had a plasma viral load (pVL) ,50 copies/mL by week 48, similar to patients in the triple-therapy arm (87.8%). 1 At week 96, this rate was 74.8% in the darunavir/ritonavir monotherapy arm. 2 The MONOI ANRS 136 study showed a 99% treatment success rate with darunavir/ritonavir triple-therapy versus a 94% success rate in those receiving darunavir/ritonavir monotherapy (d¼24.9%, 90% CI 29.1 to 20.8) in a per-protocol population. The results were not different from the intent-to-treat (ITT) population, albeit that, in the ITT analysis, non-inferiority was not reached. 3 Durable viral suppression is a key consideration in the choice of antiretroviral maintenance strategy. Thus, the long-term efficacy of darunavir/ritonavir monotherapy was evaluated in the final 96th week of the MONOI ANRS 136 study.
Methods

Study design
The MONOI trial (NCT00412551) is a randomized, open-label study. 3 To be enrolled, patients were on a stable regimen with two nucleoside reverse transcriptase inhibitors (NRTIs) and either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI), with a pVL ,400 copies/mL for ≥18 months and screening pVL ,50 copies/mL.
Patients with a history of HIV-related neurological disease or with hepatitis B coinfection could not participate. After an initial phase of 8 weeks during which patients received darunavir/ritonavir (600/100 mg twice daily) in combination with two NRTIs, patients were randomly assigned, 1 :1, to either continue the triple-drug regimen (triple-therapy arm) or to discontinue the two NRTIs (monotherapy arm). At week 48 in the two arms, in patients with pVL ,50 copies/mL, 600/100 mg of darunavir/ritonavir twice daily was switched to 800/100 mg once daily until week 96. Monitoring assessments were carried out at 8 week intervals between weeks 48 and 96. All patients provided their written informed consent. The protocol was approved by the appropriate independent ethics committees and was conducted according to the Declaration of Helsinki.
A genotypic resistance test was performed in all patients with two consecutive pVLs .50 copies/mL. Sequences of protease and reverse transcriptase genes on RNA at the time of virological failure were determined using ANRS consensus-technique primer sequences, as described at http://www.hivfrenchresistance.org.
Treatment failure was defined as either two consecutive measurements of pVL .400 copies/mL within 2 weeks or treatment modification, defined as any modification of antiretroviral therapy or discontinuation. The primary efficacy endpoint was the percentage of patients who were successfully treated by week 48. 3 Secondary efficacy endpoints included the percentage of patients with pVL ,50 copies/mL at each timepoint until week 96. For these secondary endpoints, missing data due to missed evaluations were ignored.
Statistical methods
Between-group comparisons were carried out using the Kruskal-Wallis test for continuous variables and using the Fisher's exact test for categorical variables. 
Results
Population
Overall, from the baseline ITT population of 225 randomized patients, 219 patients reached the 48 week follow-up and 211 patients reached the 96 week follow-up, with 106 patients in the monotherapy arm and 105 in the triple-therapy arm (Figure 1) .
Baseline characteristics were well balanced between the two arms, with a median duration of 8.3 years (IQR 3.7-11.3) of antiretroviral therapy and a median of 587 CD4 cells/mL (IQR 446 -749). At screening, 69.5% of patients were receiving a PI and 19.1% an NNRTI.
Virological response
By week 96, in the ITT analysis, 91 of the 103 patients (88%, 95% CI 81-94) (95% in the on-treatment analysis) allocated to the monotherapy arm and 87/104 (84%, 95% CI 75 -90) (90% in the on-treatment analysis) receiving darunavir/ritonavir triple therapy had a pVL ,50 copies/mL (P ¼ 0.42) (Figure 2 ). Throughout the 96 week follow-up, 66/112 patients (59%, 95% CI 49 -68) and 79/113 patients (70%, 95% CI 61-78) consistently had a pVL ,50 copies/mL with the darunavir/ritonavir monotherapy and the darunavir/ritonavir triple therapy, respectively (P ¼ 0.10).
Until week 48, three patients experienced virological failure in the monotherapy arm versus none in the triple-therapy arm (pVL¼ 2722 and 411 copies/mL with darunavir trough concentrations of 1120 and 3480 ng/mL, respectively; and pVL¼ 484 569 copies/mL corresponding to a treatment discontinuation). From weeks 48 to 96, virological failure occurred in six patients: two in the monotherapy arm and four in the triple-therapy arm. The main causes of the virological failure were poor compliance (in the monotherapy arm, pVL¼ 471 copies/mL and low darunavir plasma level) and treatment discontinuation (pVL ¼5134, 240 000 and 58200 copies/mL). In the remaining two patients, one in each arm, the darunavir trough concentration was within the normal range (2517 and 2967 ng/mL) despite an increase in the pVL (722 and 848 copies/mL). In all patients included in the monotherapy Darunavir/ritonavir as monotherapy in maintenance in the MONOI trial 693 JAC arm, therapeutic resumption of the initial two NRTIs led to pVL ,50 copies/mL. No associated darunavir resistance mutations or accumulation of reverse transcriptase mutations were found in the nine patients at failure. At week 96, the overall median CD4 cell count was 626 cells/ mL (IQR +488 to +835), with a median increase of +70 cells/mL (IQR 246 to +165) in the monotherapy arm and +39 cells/mL (IQR 255 to +146) in the triple-therapy arm (P ¼0.33).
Adverse events
Overall, 34 patients experienced serious adverse events between weeks 48 and 96; 12 in the monotherapy arm and 22 in the triple-therapy arm. The most serious adverse events were related to bacterial infections (n¼ 8), cardiovascular events (n¼ 4) and malignant diseases (n¼ 3). One patient in each treatment group died; one from hepatocarcinoma in the darunavir/ritonavir monotherapy arm and the other drowned. No neurological events were recorded between weeks 48 and 96 in the monotherapy arm.
Discussion
The results of this 96 week analysis from the randomized MONOI study confirm and extend those observed at 48 weeks. Overall, at week 96, the rate of virological success was in the range of standard antiretroviral therapy; 85% of the patients had a sustained pVL with darunavir/ritonavir monotherapy. 4 Nevertheless, throughout the study, the difference in the rate of virological success between the two arms, which did not exceed 5%, was in favour of the triple-therapy arm; however, at week 96 there was no statistical difference between the arms. The variation in efficacy in favour of the monotherapy arm at week 96 could be explained by missed visits at the end of the study. Importantly, the switch from 600 mg of darunavir twice daily to 800 mg of darunavir once daily in the two arms was associated with a sustained virological efficacy, confirming the results of the MONET study. 1, 2 The results are also in agreement with those from several studies, showing that high rates of patients on lopinavir/ritonavir monotherapy remained virologically suppressed after 96 weeks of follow-up. 5, 6 Despite the intermittent viraemia seen more frequently in the monotherapy arm, the longterm evaluation confirms that even in the case of virological failure there is no emergence of PI resistance-associated mutations, confirming the high barrier to resistance of darunavir. 7 No patient experienced new neurological symptoms related to HIV replication in the CSF between weeks 48 and 96, contrasting with the first weeks of the study, where two patients developed mild neurological symptoms with discordant CSF plasma HIV-RNA levels. Data are conflicting on whether the darunavir monotherapy regimen increases the risk of HIV replication in the CSF. Nevertheless, in a recent publication, Yilmaz et al. 8 demonstrated adequate and detectable levels of darunavir in the CSF, with concentrations in the range of the IC 50 for wild-type virus. In addition, another study showed detectable darunavir concentrations in the seminal compartment.
In conclusion, the MONOI study establishes that darunavir/ ritonavir monotherapy appears to be an efficacious virological strategy to contain viral replication in the long-term management of HIV-infected patients. In the era of long exposure to antiretroviral NRTIs, the choice of using PI monotherapy offers the potential to reduce cumulative NRTI-associated toxicities and should be considered as a treatment option for patients who have had a substantial period of viral suppression.
